Motolimod / VTX2337
Target: Toll-Like Receptor | Indication: Cancer
Introduction / Brief Description
Motolimod is a small-molecule agonist of toll-like receptor 8 invented by Array and licensed to VentiRx. Array received equity in VentiRx, as well as an up-front payment and the right to receive potential milestone payments and royalties on product sales. To date, Array has received $2.6 million in milestone payments and has the potential to earn $56 million if VentiRx achieves the remaining clinical and commercial milestones under the agreement.
Motolimod is designed to mobilize a patient's immune system by directly activating myeloid dendritic cells, monocytes and natural killer cells. This activation results in the production of a high level of mediators known to orchestrate the integration of both the innate and adaptive anti-tumor responses to a number of cancers. The addition of motolimod to some standard-of-care anticancer agents (chemotherapy, monoclonal antibodies) may dramatically augment the anti-tumor response. Early data from an ongoing Phase 1 trial in squamous cell carcinoma of the head and neck demonstrated that the combination was safe and well tolerated, and demonstrated activation of natural killer cells following dosing with motolimod. Two randomized Phase 2 trials in ovarian cancer and head and neck cancer are currently enrolling patients.
Click here to view the trials studying Motolimod in solid tumors.
Motolimod / VTX-2337
Clinical Cancer Research
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC